Copyright © 2021. Inderes Oyj. All rights reserved.

CellaVision AB (publ) will publish the Interim report for the first quarter, on May 10, 2022 at 7:20 CEST. The report will be available at www.cellavision.com

In connection with the release of the interim report analysts, investors and media are hereby invited to a telephone conference and audio webcast at 11:00 CEST where Simon Østergaard, President & CEO, will present and comment the report.

The presentation will be in English via a conference call or audio webcast:
https://tv.streamfabriken.com/cellavision-q1-2022

Phone number for the conference:
SE: +46 8 50 558 368

UK: +44 33 33 009 261

US: +1 64 67 224 904

No pre-registration is required. Please dial in 5-10 minutes prior to the scheduled start time to facilitate a timely start.

CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China and Japan. The company derives the majority of its revenue from the sale of analyzers.